Brief interventions for alcohol misuse among people living with HIV: a meta-analysis.
Abhishek GhoshGeetesh K SinghNidhi YadavPranshu SinghSanjana KathiravanPublished in: The American journal of drug and alcohol abuse (2023)
Background: One-third of people living with HIV (PLHIV) have alcohol misuse or alcohol use disorders which negatively affect course and outcome of HIV. Objectives: The meta-analysis sought to evaluate the effectiveness of brief interventions (BI) on alcohol and HIV outcomes in PLHIV with alcohol misuse. Methods: We included clinical trials published between 1990 and September 2022 on adults with harmful/hazardous alcohol use; only randomized clinical trials (RCTs) were included in the meta-analysis. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Clinical Trials.Gov, and the World Health Organization's International Clinical Trials Registry Platform databases. Cochrane's risk-of-bias assessment was used. Results: Eighteen studies were included in the narrative synthesis, and a meta-analysis could be performed on 13 studies. Among the included RCTs, seven showed a low risk and two showed a high risk of bias; others showed some concerns. There was no evidence of publication bias. Compared to the control, BI significantly reduces the drinks per drinking day ( N = 5, Hedge's g= -0.45, 95%CI = -0.58, -0.32) and the number of heavy drinking days ( N = 4, Hedge'sg = -0.81, 95% CI= -0.94, -0.67) between 3-6 months post-intervention. BI also reduces the odds of mortality by 42% ( N = 7, OR = 0.58, 95% CI = 0.34, 0.99) in 6-12 months. BI does not change the alcohol risk scores and transition to harmful alcohol use; it does not improve adherence to Anti-Retroviral Therapy and increase viral suppression. Conclusion: Policymakers must introduce and scale up integrated screening and brief intervention services within HIV clinics and primary care.
Keyphrases
- clinical trial
- alcohol consumption
- primary care
- systematic review
- antiretroviral therapy
- hiv positive
- hiv infected
- randomized controlled trial
- hiv testing
- human immunodeficiency virus
- case control
- chronic pain
- hepatitis c virus
- hiv aids
- men who have sex with men
- healthcare
- phase ii
- sars cov
- machine learning
- stem cells
- cardiovascular disease
- type diabetes
- high throughput
- insulin resistance
- mesenchymal stem cells
- artificial intelligence
- adipose tissue
- coronary artery disease
- deep learning
- phase iii
- health insurance
- glycemic control
- clinical evaluation